TTF-1 and Napsin A Do Not Differentiate Metastatic Lung Adenocarcinomas From Primary Esophageal Adenocarcinomas Proposal of a Novel Staining Panel

被引:13
作者
Aulakh, Kanwaijit S. [1 ]
Chisholm, Cary D. [1 ]
Smith, Daniel A. [1 ]
Speights, V. O. [1 ]
机构
[1] Scott & White Healthcare, Dept Pathol, Temple, TX USA
关键词
THYROID TRANSCRIPTION FACTOR-1; FACTOR-I EXPRESSION; TRACHEOESOPHAGEAL FISTULA; MARKER; CDX2; CARCINOMA; PULMONARY;
D O I
10.5858/arpa.2012-0305-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-When adenocarcinomas arise within the esophagus, particularly when located away from the gastroesophageal junction, it may be important in some patients to differentiate between a primary esophageal adenocarcinoma and metastasis from another site. Lung adenocarcinoma is one tumor that has been reported to frequently metastasize to the esophagus. Objectives.-To create a panel of immunohistochemical markers that can reliably distinguish between an esophageal and pulmonary primary; within the gastrointestinal pathology literature, including published articles and textbooks, common lung immunohistochemical markers, such as TTF-1, are assumed to be negative in esophageal adenocarcinoma, yet, to our knowledge, no study has yet investigated the veracity of that presumption. Design.-In this study, 24 cases each of pulmonary and esophageal adenocarcinomas were stained with TTF-1, napsin A, CDX2, 34bE12, N-cadherin, and IMP3 in an attempt to define an optimal panel for differentiation. Esophageal adenocarcinomas occurring at the gastroesophageal junction were excluded in this study because a gastric primary tumor cannot be excluded in those cases. Results.-Surprisingly, TTF-1 and napsin A were positive in similar proportions of tumors from both sites. Those markers that differentiated statistically between esophageal and pulmonary adenocarcinoma were IMP3, CDX2, and N-cadherin. Conclusions.-When differentiating the origin of a tumor as either esophageal or pulmonary, an immunohistochemical panel consisting of IMP3, CDX2, and N-cadherin is superior to either TTF-1 or napsin A.
引用
收藏
页码:1094 / 1098
页数:5
相关论文
共 17 条
[1]  
Bejarano PA, 1996, MODERN PATHOL, V9, P445
[2]   TTF-1 and HNF-3β in the developing tracheoesophageal fistula:: Further evidence for the respiratory origin of the 'distal esophagus' [J].
Crisera, CA ;
Connelly, PR ;
Marmureanu, AR ;
Lin, M ;
Rose, MI ;
Longaker, MT ;
Gittes, GK .
JOURNAL OF PEDIATRIC SURGERY, 1999, 34 (09) :1322-1326
[3]   Patterning of the "distal esophagus" in esophageal atresia with tracheo-esophageal fistula: Is thyroid transcription factor 1 a player? [J].
Crisera, CA ;
Maldonado, TS ;
Kadison, AS ;
Li, M ;
Longaker, MT ;
Gittes, GK .
JOURNAL OF SURGICAL RESEARCH, 2000, 92 (02) :245-249
[4]  
Fernández-Aceñero MJ, 2011, ROM J MORPHOL EMBRYO, V52, P171
[5]   Replacement of E-cadherin by N-cadherin in the mammary gland leads to fibrocystic changes and tumor formation [J].
Kotb, Ahmed M. ;
Hierholzer, Andreas ;
Kemler, Rolf .
BREAST CANCER RESEARCH, 2011, 13 (05)
[6]   An Oncofetal Protein IMP3 A New Molecular Marker for the Detection of Esophageal Adenocarcinoma and High-grade Dysplasia [J].
Lu, Di ;
Vohra, Poonam ;
Chu, Peigou G. ;
Woda, Bruce ;
Rock, Kenneth L. ;
Jiang, Zhong .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (04) :521-525
[7]   CDX2 immunostaining as a gastrointestinal marker - Expression in lung carcinomas is a potential pitfall [J].
Mazziotta, RM ;
Borczuk, AC ;
Powell, CA ;
Mansukhani, M .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2005, 13 (01) :55-60
[8]   TTF-1 regulates lung epithelial morphogenesis [J].
Minoo, P ;
Hamdan, H ;
Bu, D ;
Warburton, D ;
Stepanik, P ;
deLemos, R .
DEVELOPMENTAL BIOLOGY, 1995, 172 (02) :694-698
[9]   Metastatic esophageal tumors from distant primary lesions: Report of three esophagectomies and study of 1835 autopsy cases [J].
Mizobuchi, S ;
Tachimori, Y ;
Kato, H ;
Watanabe, H ;
Nakanishi, Y ;
Ochiai, A .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (06) :410-414
[10]  
Odze R.D., 2009, Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas, V2nd